Author: Ravi Shankar

TORONTO, Oct. 22, 2026 (GLOBE NEWSWIRE) — Canadian Banc Corp. (the “Company”) is pleased to announce it has completed the overnight offering of Preferred Shares (TSX: BK.PR.A) and Class A Shares (TSX: BK) of the Company. Total gross proceeds of the offering were $60.0 million.

The shares will begin trading on the Toronto Stock Exchange under the existing symbols of BK.PR.A (Preferred Shares) and BK (Class A Shares).

The Preferred Shares were offered at a price of $10.35 per Preferred Share and the Class A Shares were offered at a price of $15.40 per Class A Share.

The offering was led by National Bank Financial Inc.

The net proceeds of the offering will be used by the Company to invest in a portfolio consisting primarily of six publicly traded Canadian banks as follows:  

	Bank of Montreal	Canadian Imperial Bank of Commerce	Royal Bank of Canada
	The Bank of Nova Scotia	National Bank of Canada	The Toronto-Dominion Bank

Commissions, trailing commissions, management fees and expenses all may be associated with mutual fund investments. Investors should read the prospectus supplement to the Company’s short form base shelf prospectus dated June 18, 2025, before investing. Mutual funds are not guaranteed, their values change frequently, and past performance may not be repeated. Please read the Company’s publicly filed documents which are available at www.sedarplus.com.

Investor Relations:1-877-478-2372  Local: 416-304-4443  www.canadianbanc.com  info@quadravest.com

Leadership discusses recent FDA engagement, the technology underlying ERNA-101 and the development strategy supporting planned first-in-human clinical evaluation

Discussion features Sanjeev Luther, President and Chief Executive Officer; Dr. Christopher Rohde, developer of the technology underlying Ernexa’s platform and member of Ernexa’s Scientific Advisory Board; and Dr. Robert Pierce, Chief Scientific Officer

Access the segment here

CAMBRIDGE, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) — Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, today announced the release of a new Virtual Investor “What This Means” segment highlighting the Company’s progress advancing ERNA-101 toward the clinic and the scientific foundation supporting its broader cell therapy platform.

The discussion brings together Sanjeev Luther, President and Chief Executive Officer; Dr. Christopher Rohde, a member of Ernexa’s Scientific Advisory Board and developer of the technology underlying the Company’s platform; and Dr. Robert Pierce, Chief Scientific Officer, to discuss three key areas central to Ernexa’s next phase of development: regulatory alignment, scientific differentiation and progress toward first-in-human clinical evaluation.

At the center of the conversation is Ernexa’s pre-IND interaction with the U.S. Food and Drug Administration and what that milestone means for ERNA-101’s advancement in ovarian cancer. Mr. Luther discusses the strategic importance of the meeting, while Dr. Pierce provides additional perspective on the FDA feedback and its implications for the scientific and clinical development program.

“ERNA-101 is moving through a critical transition from preclinical development toward the clinic, and our focus is on executing each step with discipline,” said Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics. “The progress we are making across regulatory planning, IND-enabling development and clinical preparation is bringing us closer to the point where we can begin evaluating this technology in patients.”

The segment also provides a deeper look at the technology underlying Ernexa’s platform. Dr. Rohde discusses why induced mesenchymal stromal cells were selected as the foundation of the platform, the potential advantages of an allogeneic, off-the-shelf approach and the rationale for engineering ERNA-101 to express IL-7 and IL-15 within the tumor microenvironment.

“Our goal from the beginning was to build a cell therapy platform that could combine the flexibility of cellular engineering with an approach designed for practical, off-the-shelf use,” said Dr. Rohde. “ERNA-101 reflects that strategy by pairing an engineered cell platform with immune-modulating biology intended to act where it matters most, within the tumor microenvironment.”

Dr. Pierce further discusses how this underlying biology translates into Ernexa’s preclinical findings, including the program’s potential to recruit immune cells, alter the tumor microenvironment and enhance checkpoint blockade. The conversation also addresses findings from IND-enabling studies related to safety, biodistribution and tumor-homing characteristics as the Company prepares ERNA-101 for clinical development.

“The importance of the platform is not simply what it is engineered to do, but whether the biology translates into meaningful and reproducible activity,” said Dr. Robert Pierce, Chief Scientific Officer of Ernexa Therapeutics. “Our preclinical work is helping us understand that biology in greater depth and build the scientific package needed to support ERNA-101’s advancement into the clinic.”

Looking ahead, the segment outlines what investors can expect between Ernexa’s FDA interaction and initiation of a first-in-human clinical study. The discussion also explores how the underlying technology could potentially be adapted beyond the lead ovarian cancer program across additional solid tumors and therapeutic approaches.

“We believe ERNA-101 represents more than a single development program,” added Mr. Luther. “Our immediate priority is to advance the asset into the clinic, but the broader opportunity lies in demonstrating what this platform can potentially enable across oncology. That is the value we are working to unlock.”

The full Virtual Investor “What This Means” segment is available here.

For more information about ERNA-101 and the Company’s development plans, visit www.ernexatx.com

About Ernexa Therapeutics

Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for the treatment of advanced cancers. Ernexa’s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa’s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting.

ERNA-101 is the company’s lead cell therapy product, designed to activate and regulate the immune system’s response to recognize and attack cancer cells. The company’s initial focus is to develop ERNA-101 for the treatment of ovarian cancer, with the potential to address multiple difficult-to-treat solid tumors.

For more information, visit www.ernexatx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” “project,” “target,” “objective,” or the negative version of these words and similar expressions. Forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Ernexa’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: progress and possible outcomes of the Company’s lead research project, ERNA-101, and future research projects. Forward-looking statements are based upon Ernexa’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Ernexa’s risks and uncertainties, you are encouraged to review its documents filed with the SEC including its recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Ernexa does not undertake any obligation to update the forward-looking statements contained herein to reflect events that occur or circumstances that exist after the date hereof, except as required by applicable law.

Media Contact
Sharon Golubchik
RAYNZ
sharon@raynzhealth.com

Investor Contact
Jenene Thomas
JTC Team, LLC
(908) 824-0775
ERNA@jtcir.com

WISeQey Launches WISMind.AI, a Trusted Platform for Autonomous AI Agents

WISMind.AI Platform provides cryptographically verifiable identities, post-quantum protection and auditable permissions, anchored in the OISTE/WISeQey Root of Trust

Global Developer Program planned to open in the coming months, enabling developers to integrate their AI agent applications with WISMind.AI

Geneva, Switzerland – October 22, 2026 – WISeQey Corp. (formerly known as WISeKey International Holding AG, “WISeQey”) (Nasdaq/SIX: WQEY), a global quantum cybersecurity and space IoT company, today announced the launch of WISMind.AI, a trust platform built for the age of autonomous AI agents. WISMind.AI is designed to help enterprises, governments and developers verify which AI agent is acting, on whose authority, under which rules, and whether its output can be trusted.

In the coming months, WISeQey plans to open access to AI agent developers so they can integrate their applications with WISMind.AI and build on its identity, security and provenance services. The WISeQey Group of companies will also progressively integrate WISMind.AI across its own operations, on its path to becoming an Intelligent Company.

Trust infrastructure for the AI agent economy

AI agents are moving from answering questions to taking action: booking, buying, signing, negotiating and transacting with each other. Each of those actions raises a question that today’s AI stacks cannot answer reliably: who is this agent, who authorized it, and can its output be trusted?

WISMind.AI answers that question with “Know Your AI” (KYAI) and “Know your Agent” (KYA). The platform builds on WISeKey’s August 2026 strategy to extend WISeID to autonomous AI agents, through its flagship project Keystone (keystone.wiseid.com), and brings together the Group’s core technologies in a single layer designed for developers:

• WISeID and Keystone for cryptographically verifiable identities for AI agents, humans and devices
• The OISTE/WISeKey Root of Trust, the Swiss-based cryptographic anchor trusted for more than 25 years
• SEALSQ post-quantum secure semiconductors for hardware-protected, quantum-resistant credentials
• WISeQey PKI for certificate issuance, lifecycle management and digital signatures
• WeCan KYC for compliance and regulated flows

“The internet was built without an identity layer, and we spent twenty-five years fixing that for people and devices,” said Carlos Moreira, Founder, Chairman and CEO of WISeQey. “AI agents are now becoming economic actors in their own right. Before we let agents spend money, sign contracts or talk to other machines on our behalf, we must know exactly who they are, who they represent and what they are authorized to do. WISMind.AI puts that trust at the core, protected against tomorrow’s quantum threats. We plan to open developer access in the coming months to help developers build the next generation of AI agents, while keeping humans under control.”

What WISMind.AI gives AI agents

• Verifiable agent identity: each agent receives a unique WISeID Keystone credential linking it to its developer, its operator and the person or organization on whose behalf it acts.
• Delegated authority and permissions: agents carry signed, scoped mandates that define what they may do, with real-time revocation.
• Signed outputs and provenance: agents digitally sign their outputs and transactions, so recipients can verify their origin and detect tampering.
• Trusted agent-to-agent transactions: agents authenticate each other before exchanging data, value or instructions.
• Post-quantum protection: credentials can be anchored in SEALSQ Corp (Nasdaq: LAES) (“SEALSQ”) post-quantum secure hardware to resist “harvest now, decrypt later” attacks.
• Auditable consent: agent actions are recorded ina tamper-evident trail that enterprises and regulators can review.
• Privacy by design: selective-disclosure credentials let agents prove what they need to prove without exposing personal data, in line with the Digital Human Rights principles of the OISTE.ORG Foundation.

Building the Intelligent Company: WISMind.AI across the WISeQey Group

The WISeQey Group of companies will gradually integrate WISMind.AI into all of its activities, making the Group its first and largest user. The goal is to build an Intelligent Company, in which trusted AI agents work alongside employees under clear human oversight.

The rollout will cover WISeQey and its subsidiaries, SEALSQ (including Mireax, Wecan), WISeSat.Space (Nasdaq: SAIQ) (“WISeSat.Space”), SEALCOIN, extend to its special purpose technology vehicle Quantisimo, and SEALQuantumSovereign Vertical Stack investment allocation initiative, and will include:

• Staff training: programs to equip employees across the Group to work with AI agents safely and effectively.
• Adoption of the latest AI agent technologies: deploying advanced AI agents in engineering, operations, sales, finance and customer support, each with a verified WISMind.AI identity and scoped permissions.
• Trusted internal workflows: using signed outputs and auditable consent so every agent action across the Group can be traced and reviewed.
• A living reference deployment: lessons from the Group’s own transformation will feed back into WISMind.AI and be shared with developers and customers.

The integration will proceed in phases, starting with pilot functions and expanding across the Group as results are measured.

How AI agents make a company more efficient
AI agents raise efficiency by automating multi-step workflows, pulling together data that sits in separate systems, and carrying out tasks on their own, while people keep oversight of critical decisions. The WISeQey Group will focus first on five areas:

• Customer service and support: answering common inquiries, routing tickets and resolving multi-turn requests faster
• IT operations: triaging and fixing incidents, resetting passwords and provisioning software, and assisting service desk staff in real time
• Finance and accounting: reconciling data, maintaining compliance logs, handling vendor communications and speeding up reporting
• Supply chain and logistics: correlating maintenance schedules, predicting inventory or network anomalies, and optimizing workflows across systems
• Knowledge work and research: searching internal knowledge bases and drafting analyses and content, cutting time spent gathering information

The Group’s rollout will follow four principles:

1. Start with a specific bottleneck: begin with one repetitive, high-friction workflow rather than a company-wide launch.
2. Fit existing systems and permissions: integrate agents through APIs into current tools and respect each user’s existing security permissions, enforced through WISMind.AI identities.
3. Keep humans in the loop: set review checkpoints, decision logs and override rules so people guide high-stakes decisions.
4. Measure real returns: track handoff rates between agents and staff, error reduction, speed of execution and resolution times, not just the volume of automated tasks.

Call to AI agent developers: the upcoming WISMind.AI Developer Program
In the coming months, WISeQey plan to open the WISMind.AI Developer Program to developers, startups, enterprises and research teams building AI agents, so they can integrate their applications with WISMind.AI. Integration is designed to work with existing agent frameworks and to require no change to the underlying AI model.
As it opens, the program is expected to offer:

• Access to WISMind.AI APIs and SDKs to register agents, issue credentials and sign outputs
• A sandbox environment with test credentials
• Technical documentation, reference integrations and support from WISeQey engineers
• Co-marketing opportunities and a listing in the WISMind.AI directory of trusted agents

Further details on the program, including how to take part, will be shared in the coming months. WISeQey plans to share more on WISMind.AI and the program at Quantum Days in Cannes in November 2026.

About WISeQey

WISeQey Corp. (“WISeQey”), is a British Virgin Islands holding company focused on post quantum cybersecurity, digital identity, space technology and the Internet of Things (IoT). Its operating subsidiaries and technology platforms address distinct parts of this portfolio:

1. SEALSQ Corp (Nasdaq: LAES) develops secure semiconductors, public key infrastructure (PKI) and post-quantum security products.
2. WISeSat.Space (Nasdaq: SIAQ) develops space technology and secure satellite communications, particularly for IoT applications.
3. WISeID provides digital identity, authentication, secure access and digital signing for individuals, enterprises and connected devices.
4. WISe.ART Corp operates the WISe.ART marketplace, which uses blockchain technology to support trusted digital asset and NFT transactions.
5. SEALCOIN AG develops decentralized physical infrastructure network (DePIN) technology and the SEALCOIN platform.

Each subsidiary contributes to WISeQey’s mission of securing the internet while focusing on their respective areas of research and expertise. Their technologies seamlessly integrate into the comprehensive WISeQey platform. WISeQey secures digital identity ecosystems for individuals and objects using blockchain, AI, and IoT technologies. With over 1.6 billion microchips deployed across various IoT sectors, WISeQey plays a vital role in securing the Internet of Everything. Trusted by the OISTE/WISeQey cryptographic Root of Trust, WISeQey provides secure authentication and identification for IoT, blockchain, and AI applications. The WISeQey Root of Trust ensures the integrity of online transactions between objects and people. For more information on WISeQey’s strategic direction and its subsidiary companies, please visit www.wisekey.com.

Forward-Looking Statements

This communication expressly or implicitly contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our business strategy, financial performance, results of operations, market data, , events or developments that we expect or anticipate will occur in the future, as well as any other statements which are not historical facts. Words such as “aims,” “ambition,” “anticipates,” “expects,” “intends,” “plans,” “will” and similar expressions are intended to identify forward-looking statements. Although we believe that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates which are inherently subject to significant uncertainties and contingencies, many of which are beyond our control. Actual results may differ materially from those expressed or implied by such forward-looking statements. Important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include WISeQey’s ability to continue beneficial transactions with material parties, including a limited number of significant customers; and market demand and semiconductor industry conditions. WISeQey is providing this communication as of this date and do not undertake to update any forward-looking statements as a result of new information, future events or otherwise.

This press release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities, and it does not constitute an offering prospectus within the meaning of the Swiss Financial Services Act (“FinSA”), the FinSA’s predecessor legislation or advertising within the meaning of the FinSA. Investors must rely on their own evaluation of WISeQey and its securities, including the merits and risks involved. Nothing contained herein is, or shall be relied on as, a promise or representation as to the future performance of WISeQey. Given the risks and uncertainties described herein, you should not place undue reliance on forward-looking statements as a prediction of actual results.

Press and Investor Contacts

WISeQey Corp. Company Contact: Carlos Moreira Chairman & CEO Tel: +41 22 594 3000 info@wisekey.com

WISeQey Investor Relations (US)  The Equity Group Inc. Lena Cati Tel: +1 212 836-9611 lena.cati@theequitygroup.com

LONDON, Oct. 22, 2026 (GLOBE NEWSWIRE) — Willis, a WTW business (NASDAQ: WTW), today announced the launch of its new global Defense and Security initiative. The coordinated, sector-led platform connects capabilities across Willis’ specialties and geographies to help defense and security organizations understand interconnected risks, strengthen resilience and make better-informed decisions. The initiative is led at Willis by Jennifer Caldarella.

The scale of the defense and security sector, and the risks that come with it, are growing fast. The world’s 100 largest arms-producing and military services companies generated a record US$679 billion in arms revenues in 2024¹. Yet pressure on the industrial base that supports them remains significant. In the US, defense industrial security oversight recorded 815 security violations during the 2025 financial year and 1,032 unresolved security vulnerabilities at cleared contractor facilities since September 2025².

Defense and security organizations are operating at the center of profound geopolitical, technological and economic change. Global military expenditure reached nearly US$2.9 trillion in 2025³ and could approach US$4.7-6.6 trillion by 2035⁴. But capital alone does not create capability, says Willis. Major US defense acquisition programs already take more than 12 years on average to deliver initial capability⁵, widening the gap between investment and operational readiness. Closing it requires organizations to manage cyber, operational, supply chain, regulatory and contracting requirements, constrained insurance capacity and resilience risks that can delay or undermine delivery.

The sector is also changing. Drones, autonomous maritime technology, AI-enabled warfare systems and advanced digital capabilities are transforming how organizations operate, assess risk and deliver mission-critical outcomes. At the same time, a new generation of technology-led companies is entering the market, bringing innovative business models and new risk dimensions.

As organizations invest in AI-enabled systems, autonomy, advanced digital capabilities and resilient infrastructure, they face liability, cyber, resilience, operational assurance and regulatory oversight challenges that traditional risk management approaches were not designed to address. This is driving demand for specialized risk advice, insurance solutions and resilience capabilities tailored to fast-moving, interconnected exposures.

Willis is responding through a coordinated defense and security sector focus, giving clients access to integrated expertise across risk transfer, risk advisory and analytics, cyber and data security, crisis management, claims, risk engineering, operational resilience, workforce risk, and capital and transaction advisory. By connecting specialists across its global business in 140 countries, Willis helps organizations better understand risk across operations, assets, supply chains and strategic investments.

Alastair Swift, Head of Global Specialties at Willis, said: “The defense and security sector plays an increasingly important role in national resilience, economic stability and technological innovation. Organizations are making critical decisions against a backdrop of geopolitical uncertainty, rapid change and evolving regulation. Our Defense and Security initiative is a long-term commitment to the sector. It brings together the breadth of Willis’ expertise and global market access to meet clients’ priorities, challenges and ambitions, helping them better understand, quantify and mitigate their risks and secure the most appropriate insurance and capital solutions available.”

Jennifer Caldarella, Global Defense Lead at Willis, said: “The defense and security sector is entering one of the most significant investment cycles in its history. But investment alone does not create capability. Organizations must navigate technology transformation, cyber risk, operational resilience, regulatory complexity and long delivery timelines to realize the full value of those investments. The challenge is not only where to invest, but how to manage the risks that can delay progress or undermine outcomes. Our role is to help clients understand those risks and build the resilience needed to deliver on their strategic objectives, both today and in the years ahead.”

Find out more here.

Sources

1. SIPRI, The SIPRI Top 100 Arms-Producing and Military Services Companies, 2024
2. GAO, Industrial Security (GAO-26-107861)
3. SIPRI, Trends in World Military Expenditure, 2025
4. United Nations, The True Cost of Peace
5. GAO, Weapons Systems Annual Assessment 2026

About WTW

At WTW (NASDAQ: WTW), we provide data-driven, insight-led solutions in the areas of people, risk and capital. Leveraging the global view and local expertise of our colleagues serving 140 countries and markets, we help organizations sharpen their strategy, enhance organizational resilience, motivate their workforce and maximize performance. Working shoulder to shoulder with our clients, we uncover opportunities for sustainable success—and provide perspective that moves you. Learn more at www.wtwco.com

Media contacts

Jo Barrett	jo.barrett@wtwco.com
Lauren Ryan	lauren.ryan@wtwco.com

Press Release no. 05/2026

cBrain establishes U.S. subsidiary to support continued market expansion

Copenhagen, October 22, 2026

cBrain^® (NASDAQ: CBRAIN) has established cBrain Inc., a wholly owned U.S. subsidiary, and completed its registration in the U.S. federal government’s System for Award Management (SAM.gov).

The establishment of the subsidiary and the SAM.gov registration mark further steps in cBrain’s U.S. expansion strategy, reflecting continued progress and growing business opportunities in the American government software market.

The SAM.gov registration enables cBrain Inc. to participate directly in U.S. federal government procurement processes, while the new subsidiary provides a permanent corporate presence to support local customer relationships, contracting, service delivery and future business development.

cBrain has made significant progress in the U.S. market during 2026. Following a successful pilot project, the company was awarded its first contract with the State of California in August 2026. In parallel, cBrain has initiated activities with U.S. federal and state government agencies, demonstrating the relevance of F2 for modernizing government operations through standard software and artificial intelligence.

The U.S. market represents a strategic growth opportunity for cBrain. Pioneering a new generation of integrated enterprise software built specifically for government, cBrain offers F2, an AI-enabled commercial off-the-shelf (COTS) platform that combines case management, workflow automation, document management and digital services in one unified solution, designed to modernize government operations at scale.

The establishment of cBrain Inc. and completion of the federal government registration strengthen cBrain’s foundation for continued growth in the American market and support the company’s strategy of expanding internationally through the sale of standard software for government.

The announcement does not change cBrain’s previously communicated financial expectations for 2026.

About cBrain

cBrain^® (NASDAQ: CBRAIN) is pioneering a new generation of integrated enterprise software, built specifically for government.

The cBrain F2 software brings together case management, document management, workflow automation, digital services and artificial intelligence in one unified platform. Delivered as commercial off-the-shelf (COTS) software, F2 enables government organizations to accelerate digital transformation without the complexity and cost of traditional custom-built IT systems.

F2 is used by more than 75 public authorities in Denmark, including the Danish government ministries, providing a proven foundation for international expansion.

Building on Denmark’s position as a global leader in digital government, cBrain is bringing the Danish model of digital government to the world. Today, F2 is used by government organizations across five continents, demonstrating how the Danish model can be reused and scaled internationally through standard software.

For more information, visit www.cbrain.com.

Best regards

Per Tejs Knudsen, CEO

nquiries regarding this Press Release may be directed to 

Lars Møller Christiansen, CFO & Head of Investor Relations, cBrain A/S, ir@cbrain.com, +45 24429300

Attachment

• Press Release no. 2026-05 (cBrain Inc.)

WINSTON-SALEM, N.C., Oct. 22, 2026 (GLOBE NEWSWIRE) — ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, October 27, 2026, at 10:30 AM ET. To register, click here.

The event will feature nephrology leader and researcher Katherine Tuttle, MD, who will join Company management to discuss new insights into rilparencel’s mechanism of action from research presented at the American Society of Nephrology (ASN) Kidney Week 2026, as well as the potential role of rilparencel in treating patients with advanced CKD and type 2 diabetes (T2D).

Anthony Conway, PhD, ProKidney’s Head of Research and Development, will review key findings from the Company’s ASN presentations and discuss how they contribute to the understanding of rilparencel’s multifactorial mechanism of action. Dr. Tuttle will provide her clinical perspective on the findings, the remaining unmet need for patients with advanced Stage 3b/4 CKD and T2D despite recent therapeutic advances, and where rilparencel may fit within the evolving treatment paradigm. Company management will also provide a corporate update during the event.

A live question and answer session will follow the formal presentations.

About Katherine Tuttle, MD
Katherine R. Tuttle, MD, FASN, FACP, FNKF, is Executive Director for Research at Providence Inland Northwest Health and Professor of Medicine at the University of Washington. Dr. Tuttle earned her medical degree and completed her residency in Internal Medicine at Northwestern University in Chicago, Illinois. She was a fellow in Metabolism and Endocrinology at Washington University in St. Louis, Missouri. Her Nephrology fellowship training was performed at University of Texas Health Science Center in San Antonio, Texas. Dr. Tuttle’s major research interests are in diabetes and chronic kidney disease. She has published over 450 original articles and served as Associate Editor for the Clinical Journal of the American Society of Nephrology and the American Journal of Kidney Disease. Dr. Tuttle has received many honors and awards including the John P. Peters Lifetime Achievement Award from the American Society of Nephrology, Medal of Excellence from the American Association of Kidney Patients, Garabed Eknoyan Award from the National Kidney Foundation, the YWCA Woman of Achievement Award in Science, and two Outstanding Clinical Faculty Awards at the University of Washington. Dr. Tuttle served on the inaugural Board of Directors for the Kidney Health Initiative and has chaired working groups and committees for organizations including the NIDDK/NIH, the National Kidney Foundation, the American Society of Nephrology, the International Society of Nephrology, and the American Diabetes Association.

About ProKidney Corp.
ProKidney, a pioneer in the treatment of CKD through innovations in cell therapy, was founded in 2015 after a decade of research. ProKidney’s lead investigational product candidate, rilparencel (also known as REACT^®), is a first-in-class, patented, proprietary autologous cell therapy with regenerative medicine advanced therapy designation that is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes. For more information, please visit www.prokidney.com.

Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. ProKidney’s actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the achievement and timing of the topline data readout of the Company’s PROACT 1 trial and other milestones provided, the Company’s beliefs that its Phase 3 REGEN-006 (PROACT 1) trial could be sufficient to support a potential BLA submission and full regulatory approval, that eGFR slope can be used as a surrogate endpoint on an accelerated approval pathway for rilparencel, expectations with respect to financial results and expected cash runway, including the Company’s expectation that current cash will support operating plans into mid-2027, future performance, development and commercialization of products, if approved, the potential benefits and impact of the Company’s products, if approved, potential regulatory approvals, the size and potential growth of current or future markets for the Company’s products, if approved, the advancement of the Company’s development programs into and through the clinic and the expected timing for reporting data, the making of regulatory filings or achieving other milestones related to the Company’s product candidates, and the advancement and funding of the Company’s developmental programs, generally. Most of these factors are outside of the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: disruptions to our business or that may otherwise materially harm our results of operations or financial condition as a result of our recent domestication to the United States; the inability to maintain the listing of the Company’s Class A common stock on Nasdaq; the inability of the Company’s Class A common stock to remain included in various indices and the potential negative impact on the trading price of the Class A common stock if excluded from such indices; the inability to implement business plans, forecasts, and other expectations or identify and realize additional opportunities, which may be affected by, among other things, competition and the ability of the Company to grow and manage growth profitably and retain its key employees; the risk of downturns and a changing regulatory landscape in the highly competitive biotechnology industry; the risk that results of the Company’s clinical trials may not support approval; the risk that the FDA could require additional studies before approving the Company’s drug candidates; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to compete with other companies currently marketing or engaged in the biologics market and in the area of treatment of kidney diseases; the size and growth potential of the markets for the Company’s products, if approved, and its ability to serve those markets, either alone or in partnership with others; the Company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; the Company’s intellectual property rights; uncertainties inherent in cell therapy research and development, including the actual time it takes to initiate and complete clinical studies and the timing and content of decisions made by regulatory authorities; the fact that interim results from our clinical programs may not be indicative of future results; the impact of geo-political conflict on the Company’s business; and other risks and uncertainties included under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. The Company cautions readers that the foregoing list of factors is not exclusive and cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

ProKidney Contact
Ethan Holdaway
Ethan.Holdaway@prokidney.com

Media Contact
Audra Friis
audrafriis@sambrown.com

Investor Relations Contact
Daniel Ferry
Daniel@lifesciadvisors.com 

Company targets higher throughput and sales at Eagle Springs with nameplate capacity of approximately 5,000 barrels of crude oil per day

WOODS CROSS, Utah, Oct. 22, 2026 (GLOBE NEWSWIRE) — Sky Quarry Inc. (NASDAQ: SKYQ) (“Sky Quarry” or the “Company”), an energy infrastructure company focused on domestic refining and resource development, today announced that refined petroleum production is underway at its Eagle Springs Refinery near Ely, Nevada. Operated by wholly owned subsidiary Foreland Refining Corporation, the refinery produces diesel and distillate fuels, vacuum gas oil, naphtha, and liquid paving asphalt.

Production follows the Company’s receipt of its Nevada air permit in September, completion of refinery repairs and upgrades, and successful restart. With production underway, Sky Quarry is focused on increasing throughput, expanding product sales, and generating operating cash flow.

“Moving from a refinery restart to actual petroleum production is a tremendous milestone for Sky Quarry and our shareholders,” said Marcus Laun, interim Chief Executive Officer of Sky Quarry. “The plant is operating as expected. We are excited by the support we are getting from our community of suppliers and customers. The refinery operates in a niche within the larger regional petroleum market.”

Laun continued, “Our refinery produces the products that keep the economy moving — diesel for transportation and industry, vacuum gas oil and naphtha for downstream markets, and asphalt for roads and infrastructure. We now have the opportunity to turn those products into meaningful revenue and cash flow while steadily increasing production.”

Diesel Market Opportunity

Salt Lake City diesel rack prices indicated a crack spread of approximately $133 to $136 per barrel as of October 21, 2026, compared with approximately $33 per barrel in January, which represents an increase of about 300%.

The lower wholesale diesel price used in the October comparison was approximately $231 per barrel. Strong regional diesel pricing presents an opportunity for Sky Quarry as refinery throughput increases.

Production begins against a favorable diesel market backdrop. In its October 2026 Short-Term Energy Outlook, the U.S. Energy Information Administration forecasted diesel crack spreads remaining above historical averages through 2027.

The $133 to $136 range is a regional pricing indicator calculated from market benchmarks. Sky Quarry’s actual refining margins will reflect its own feedstock acquisition costs, transportation, operating expenses, product yields, and realized sales prices.

Pricing basis: The calculation uses October 21 Salt Lake City OPIS Low Rack GROSS and Rack Average GROSS diesel prices displayed by Flyers Energy of $5.4991 and $5.5633 per gallon, respectively, multiplied by 42 gallons per barrel, less a delayed December WTI futures quote of $97.86 per barrel observed at 2:35 p.m. Central time on October 21. The resulting differences of $133.10 and $135.80 per barrel are rounded. The rack postings and futures quote are as of different times.

Increasing Throughput and Commercial Sales

Eagle Springs is Nevada’s only crude oil refinery, with a stated nameplate processing capacity of approximately 5,000 barrels of crude oil per day. The facility includes crude oil processing, product handling, and storage infrastructure designed to support a range of feedstocks and refined products.

The refinery’s eastern Nevada location provides access to crude supplies from Nevada, Utah, and surrounding producing regions, with proximity to petroleum product markets throughout the Intermountain West. Sky Quarry intends to increase throughput progressively while strengthening operating reliability, securing additional crude supplies, optimizing product yields, and expanding commercial sales arrangements.

The Company is also evaluating opportunities to broaden its crude sourcing network, including increased use of regional supplies and potential future integration with its PR Spring resource development operations in Utah. Management expects to provide additional updates as production volumes increase and commercial operations develop.

Products Serving Western U.S. Energy Markets

Diesel and distillate fuels. Products for regional transportation, agriculture, mining, and industrial fuel markets.

Vacuum gas oil. An intermediate product marketed to refiners and industrial customers for further processing into transportation fuels and other petroleum products.

Naphtha. A light petroleum fraction used as feedstock for gasoline blending, further refining, and other industrial applications.

Liquid paving asphalt. Products for road construction, paving, and infrastructure maintenance.

These products provide multiple revenue opportunities and are expected to allow the Company to optimize its product mix based on feedstock characteristics, operating conditions, and regional commodity prices.

About Sky Quarry Inc.

Sky Quarry Inc. (NASDAQ: SKYQ) is an energy infrastructure company focused on domestic refining and resource development.

Through its wholly owned subsidiary, Foreland Refining Corporation, the Company operates the Eagle Springs Refinery near Ely, Nevada, the state’s only crude oil refinery, producing diesel, vacuum gas oil, naphtha and liquid paving asphalt.

Sky Quarry is also developing its PR Spring facility in Utah, where the Company is advancing technologies for hydrocarbon recovery from oil-bearing resources and waste asphalt shingles.

For more information, visit www.skyquarry.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions created by the U.S. Private Securities Litigation Reform Act of 1995. These statements include, among other things, expectations, beliefs and plans concerning the Company’s operations, strategy, refinery throughput, production growth, future revenue and cash flow, product sales, operating margins, feedstock availability and pricing, customer demand and market conditions, financing activities and development of the Company’s other assets. Forward-looking statements are not guarantees of future performance and can be identified by words such as “aim,” “could,” “evaluate,” “expect,” “intend,” “may,” “plan,” “potential,” “target,” “will” and other similar expressions.

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including operational interruptions, equipment reliability, regulatory compliance, crude oil supply and pricing, refining margins, transportation costs, access to capital, market demand, competition, general economic conditions and other risks identified in the Company’s filings with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release are made as of the date hereof, and except as required by law, the Company undertakes no obligation to update or revise any forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements.

Investor Relations Contact

Sky Quarry Inc.
Email: ir@skyquarry.com
Website: www.skyquarry.com

Company to host conference call on November 5, 2026, at 4:30 p.m. ET

MOUNTAIN VIEW, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) — RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath^®, a patented, FDA-cleared drug-delivery device, today announced that it will release third quarter 2026 financial results and business highlights after market close on Thursday, November 5, 2026. RenovoRx will host a conference call and webcast at 4:30 p.m. ET following the release.

During the call, management will discuss the Company’s commercial execution, the drivers of its commercial success, and the foundation it believes is in place for continued revenue growth and cash generation.

Management will also provide an update on clinical progress expected to support greater physician adoption of RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™) platform, enabled by RenovoCath, and expand its use in additional solid tumors indications.

Conference Call Details
Live Call Dial-in:	1-844-826-3033 (U.S. and Canada toll free) 1-412-317-5185 (International)
Webcast:	Access here
Replay:	1-844-512-2921 (U.S. and Canada toll free) 1-412-317-6671 (International) Access ID: 10212350

About RenovoRx, Inc.
RenovoRx, Inc. (Nasdaq: RNXT) is a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath^®, a patented, U.S. Food and Drug Administration (FDA)-cleared local drug-delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™) platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and its mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. RenovoRx is actively commercializing its TAMP technology and FDA-cleared RenovoCath as a standalone device. For its first full year of commercial efforts in 2025, RenovoRx generated approximately $1.1 million in RenovoCath sales, followed by record quarterly revenue of $909,000 in the second quarter of 2026. RenovoRx is actively working to expand the number of medical institutions initiating new RenovoCath orders, including esteemed, high-volume National Cancer Institute-designated centers.

RenovoRx is also evaluating its novel drug-device combination oncology product candidate intra-arterial gemcitabine delivered via RenovoCath (known as IAG) in the ongoing Phase III TIGeR-PaC trial. IAG is being evaluated by the Center for Drug Evaluation and Research (the drug division of the FDA) under a U.S. investigational new drug application that is regulated by the FDA’s 21 CFR 312 pathway. IAG utilizes RenovoCath, which is FDA-cleared for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. RenovoRx achieved full enrollment in the TIGeR-PaC trial in August 2026, with completion of the trial expected in the first half of 2027 and topline data readout expected in the second half of 2027.

The IAG combination product candidate, enabled by the RenovoCath device, is currently under investigation and has not been approved for commercial sale. RenovoCath with gemcitabine received Orphan Drug Designation (ODD) for pancreatic cancer and bile duct cancer, and oxaliplatin has received ODD for pancreatic cancer, each of which provides seven years of market exclusivity upon new drug application approval by the FDA.

For more information, visit www.renovorx.com. Follow RenovoRx on Facebook, LinkedIn, and X.

Cautionary Note Regarding Forward-Looking Statements

This press release, the conference call described herein, and statements of the Company’s management and third parties made in connection therewith contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding (i) our clinical trials and studies, (ii) the potential for our product candidates to treat or provide clinically meaningful outcomes for certain medical conditions or diseases, and (iii) our efforts to commercialize our RenovoCath and TAMP technology. Statements that are not purely historical are forward-looking statements. These and other forward-looking statements contained herein are based upon our current expectations and beliefs regarding future events, many of which, by their nature, are inherently uncertain, outside of our control, and involve assumptions that may never materialize or may prove to be incorrect. These may include estimates, projections, and statements relating to our research and development plans, intellectual property development, clinical trials, our therapy platform, business plans, financing plans, objectives, and expected operating results, which are based on such current expectations and assumptions that are subject to significant known and unknown risks and uncertainties that may cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These statements may be identified using words such as “may,” “expects,” “plans,” “aims,” “anticipates,” “believes,” “forecasts,” “aim,” “goal,” “estimates,” “intends,” and “potential,” or derivatives of these terms or other comparable terminology regarding RenovoRx’s statements about the future, although not all forward-looking statements contain these words. Risks, uncertainties and assumptions that could cause actual events to differ materially from those projected or indicated by forward-looking statements, include, without limitation: (i) the risk that our exploration of commercial opportunities for our TAMP technology may not lead to viable, revenue generating operations; (ii) circumstances which would adversely impact our ability to efficiently utilize our cash resources on hand or raise additional funding; (iii) the timing of the initiation, progress, and potential results (including the results of interim analyses) of our preclinical studies, clinical trials, and our research programs; (iv) the possibility that interim results may not be predictive of the outcome of our clinical trials, which may not demonstrate sufficient safety and efficacy to support regulatory approval of our product candidate; (v) that applicable regulatory authorities may disagree with our interpretation of the data, research, and clinical development plans and timelines, and the regulatory process for our product candidates; (vi) future potential regulatory milestones for our product candidates, including those related to current and planned clinical studies; (vii) our ability to use and expand our therapy platform to build a pipeline of product candidates; (viii) our ability to advance product candidates into, and successfully complete, clinical trials; (ix) the timing or likelihood of regulatory filings and approvals; (x) our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our clinical trials; (xi) the commercialization potential of our product candidates, if approved; (xii) our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; (xiii) future strategic arrangements and/or collaborations and the potential benefits of such arrangements; (xiv) our estimates regarding expenses, future revenue, capital requirements, needs for additional financing, our ability to obtain additional capital and our ability to maintain the listing of our common stock on Nasdaq; (xv) the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; (xvi) our ability to retain the continued service of our key personnel and to identify, and hire and retain additional qualified personnel; (xvii) the scope of protection we are able to establish and maintain for intellectual property rights, including our therapy platform, product candidates, and research programs; (xviii) our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; (xix) the pricing, coverage, and reimbursement of our product candidates, if approved; and (xx) developments relating to our competitors and our industry, including competing product candidates and therapies. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in documents that we file from time to time with the Securities and Exchange Commission, which can be accessed at https://ir.renovorx.com/sec-filings.

As a result of the foregoing, readers are cautioned to not place undue reliance on forward-looking statements, which do not represent promises or guarantees by RenovoRx. Forward-looking statements included herein are made as of the date hereof, and RenovoRx does not undertake any obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as required by law.

Investor Contact:
ICR Healthcare
Stephanie Carrington or Adanna G. Alexander, PhD
T: 646-277-1282
RenovoRx@ICRHealthcare.com

Media Contact:
STiR Communications
Hannah Williams
T: 803-521-1214
hannah@stir-communications.com

COLUMBUS, Ohio, Oct. 22, 2026 (GLOBE NEWSWIRE) — Worthington Enterprises Inc. (NYSE: WOR), a designer and manufacturer of market-leading brands that improve everyday life by elevating spaces and experiences, today announced it will participate in next month’s Baird Global Industrial Conference in Chicago. President and Chief Executive Officer Joe Hayek and Vice President and Chief Financial Officer Colin Souza will share the company’s strategies for accelerating long-term growth and shareholder value by leveraging the proven Worthington Business System and its three pillars—innovation, transformation and M&A.

The presentation is scheduled for Thursday, November 12 at 1:35 p.m. ET. Individuals unable to attend the in-person event may register to watch virtually at this link. A replay of the session will be posted in the Investor Relations section of the Worthington Enterprises website.

2026 Investor and Analyst Day
Prior to the Baird Conference, Worthington Enterprises is hosting an Investor and Analyst Day in New York City on November 10 at 9:30 a.m. ET. Hayek and Souza, as well as Jimmy Bowes, president, Building Performance Solutions and Steve Caravati, president, Trade & Specialty Solutions, will provide an update on the company’s strategy, financial performance and long-term growth opportunities.

Online participants should register at this link: https://worthington-enterprises-investor-day-2026-11-10.open-exchange.net. Investors and analysts interested in attending the in-person event should contact Marcus Rogier at marcus.rogier@wthg.com.

About Worthington Enterprises
Worthington Enterprises Inc. (NYSE: WOR) is a designer and manufacturer of market-leading brands that improve everyday life by elevating spaces and experiences. Building Performance Solutions (formerly Building Products) delivers essential engineered products that enhance performance across residential and commercial buildings, including critical facilities such as data centers. Its products support building systems, and climate and comfort applications. The segment primarily serves OEMs and distributors. Trade & Specialty Solutions (formerly Consumer Products) includes market-leading brands used by professional tradespeople and consumers across tools, portable propane and helium and other specialty applications. The Worthington Enterprises portfolio includes Balloon Time®, Bernzomatic®, ClarkDietrich, Coleman® propane cylinders, Elgen, General®, HALO™, LEVEL5 Tools®, Ragasco®, Roof Hugger®, Well-X-Trol® and Worthington Armstrong Venture (WAVE), among others.

Headquartered in Columbus, Ohio, Worthington Enterprises employs approximately 4,000 people throughout North America and Europe.

Founded in 1955 as Worthington Industries, Worthington Enterprises follows a people-first Philosophy with earning money for its shareholders as its first corporate goal. Worthington Enterprises achieves this outcome by empowering its employees to innovate, thrive and grow with leading brands in attractive markets that improve everyday life. The company engages deeply with local communities where it has operations through volunteer efforts and The Worthington Companies Foundation, participates actively in workforce development programs and reports annually on its corporate citizenship and sustainability efforts. For more information, visit worthingtonenterprises.com.

Forward-Looking Statements
Statements by Worthington Enterprises that are not limited to historical information constitute “forward-looking statements” under federal securities laws. Forward-looking statements are subject to various risks, uncertainties and other factors that may cause actual results to differ materially from those expected by Worthington Enterprises. Readers should evaluate forward-looking statements in the context of such risks, uncertainties and other factors, many of which are described in Worthington Enterprises’ filings with the Securities and Exchange Commission (“SEC”). Forward-looking statements are qualified by the cautionary statements included in Worthington Enterprises’ SEC filings and other public communications. This press release speaks only as of the date hereof. Worthington Enterprises does not undertake any obligation to update or revise its forward-looking statements except as required by applicable law or regulation.

Sonya L. Higginbotham
Senior Vice President
Chief of Corporate Affairs, Communications and Sustainability
614.438.7391
sonya.higginbotham@wthg.com

Marcus A. Rogier
Treasurer and Investor Relations Officer
614.840.4663
marcus.rogier@wthg.com

200 Old Wilson Bridge Rd.
Columbus, Ohio 43085
WorthingtonEnterprises.com

VANCOUVER, British Columbia, Oct. 22, 2026 (GLOBE NEWSWIRE) — Encore Technologies Corp. (“Encore” or the “Company”) (CSE: ENCR) is pleased to highlight a major on-orbit technology milestone achieved by portfolio company, Solstar Space Co. (“Solstar”), following the successful demonstration of Solstar’s space communications technology during an ongoing NASA proximity operations mission.

Highlights:

• NASA Mission Success: Solstar successfully demonstrated its technology in space during an operational NASA mission.
• Technology Validated in Orbit: Solstar connected two spacecraft and helped deliver NASA mission data back to Earth on the Iridium Network.
• Encore Expands Space Focus: Following its US$1.16 million investment in Solstar, Encore is strengthening its focus and leadership in the rapidly growing space sector.

The milestone comes shortly after Encore’s approximately US$1.16 million strategic investment in Solstar and represents an important validation of the investment thesis behind Encore’s growing exposure to the commercial space economy.

Encore is also announcing the appointment of Company co-founder and capital markets executive Matthew Sroka to its Board of Directors as part of a board reconstitution that will see founding shareholder and Director James Reid resign from the board of directors.

With its investment in Solstar and the recent addition of former Commander of the Royal Canadian Air Force Lieutenant-General (Ret’d) Michael Hood as Strategic Advisor, Encore is building deeper expertise and exposure within the rapidly developing commercial and defence space infrastructure markets.

Solstar Technology Successfully Deployed in Operational NASA Mission

Solstar recently demonstrated its Deke™ Space Communicator during NASA’s R5-S10 proximity operations mission involving NASA’s CubeSat and Momentus’ Vigoride-7 orbital service vehicle.

Solstar’s technology established a space-to-space Wi-Fi connection between the spacecraft, capturing mission imagery and sensor data and relaying mission-critical information back to NASA personnel at Johnson Space Center through the Iridium satellite network. During approximately 30 minutes of proximity operations, Deke collected more than 2,300 files, including imagery and optical, infrared and LiDAR sensor data.

The mission represents a significant milestone for Solstar, advancing its communications architecture from technology development to demonstrated on-orbit capability during an operational NASA mission. The demonstration validated key elements of an end-to-end communications architecture designed to support increasingly connected and autonomous space operations, with potential applications across satellites, orbital servicing, commercial space stations and future lunar operations.

For Encore, the successful mission provides important validation of its investment thesis in Solstar, demonstrating the technology in a live orbital environment alongside NASA, Momentus and Iridium, while reinforcing Encore’s growing focus on the commercial space economy.

Solstar’s Joint News Release with NASA

Stephen Kukucha, Chief Executive Officer of Encore, commented:

“When we invested in Solstar, we believed communications infrastructure would become increasingly critical as activity in orbit expands. What Solstar has now accomplished with NASA is an important validation of that thesis.

This wasn’t a laboratory demonstration. Solstar’s technology operated in space during a NASA mission, connected spacecraft in orbit and helped move mission data back to Earth through the Iridium network. That is an important distinction.

We believe the next generation of space infrastructure will require persistent and reliable connectivity between spacecraft, operators and Earth. Solstar is building technology aimed directly at that requirement, and we believe this successful mission materially strengthens its position as the commercial space economy develops.”

Board Reconstitution

Encore is also pleased to announce the appointment of Matthew Sroka, a co-founder of Encore and Managing Partner of Three Peaks Capital, to the Company’s Board of Directors.

Mr. Sroka has more than 16 years of experience across international capital markets, corporate finance and company formation. He has played a senior role in more than $200 million of public and private financings and has helped build, finance and structure companies and transactions across multiple international markets and stock exchanges. His experience spans capital formation, corporate structuring, M&A, institutional investor development and the advancement of emerging companies from early-stage formation through public-market growth.

Mr. Sroka’s appointment adds significant capital markets and corporate development experience to the Board as Encore evaluates opportunities to expand its exposure to emerging technology and infrastructure markets.

In connection with the Board reconstitution, James Reid will resign as a director of the Company.

Encore extends its sincere appreciation to Mr. Reid for his contributions as a founding director and for his important role in guiding the Company through its formation and successful listing on the Canadian Securities Exchange.

About Solstar Space Company

Solstar is a U.S.-based communications infrastructure company developing connectivity solutions for the growing space economy. The Company is focused on enabling persistent communications for spacecraft, commercial space operators, government agencies and future space-based infrastructure through a combination of communications hardware, software and communications services. Solstar’s DEKE Space Communicator is currently operating in orbit, supporting the Company’s mission of extending connectivity beyond traditional terrestrial networks.

About Encore Technologies Inc.

Encore Technologies Inc. is a technology-focused public company advancing intelligent infrastructure solutions and evaluating strategic opportunities in emerging technology sectors. The Company seeks to identify technologies and partnerships that have the potential to improve connectivity, operational efficiency and long-term infrastructure resilience.

For further information contact:
Stephen Kukucha
Chief Executive Officer
Tel: (604) 398-4786

Caution Regarding Forward-Looking Information

This news release contains “forward-looking information” within the meaning of applicable Canadian securities laws. Forward-looking information includes statements regarding, the proposed Financing, the proposed Investment, the execution of definitive agreements, the use of proceeds, anticipated strategic benefits, potential future collaboration opportunities between Encore and Solstar, the completion of the transactions described herein, and other statements that are not historical facts. Forward-looking information is generally identified by words such as “expects,” “intends,” “anticipates,” “believes,” “plans,” “estimates,” “may,” “could,” “would,” “should,” and similar expressions. Forward-looking information reflects management’s current beliefs and assumptions and is subject to a number of known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied.

Readers are cautioned not to place undue reliance on forward-looking information. The Company undertakes no obligation to update or revise forward-looking information except as required by applicable law.

The CSE has neither approved nor disapproved the contents of this news release. The CSE does not accept responsibility for the adequacy or accuracy of this news release.